CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sigilon Therapeutics, a biopharmaceutical company that discovers and develops shielded living therapeutics, today announced that two members of its executive leadership team will present at the 2018 Cell & Gene Meeting on the Mesa in La Jolla, California.
Chief Executive Officer Rogerio Vivaldi will provide an overview of the company and its pioneering work in living therapeutics in his presentation on Thursday, October 4, 2018 at 1:45pm PT/4:45 pm ET.
Chief Strategy Officer and Head of Operations Devyn Smith will speak to challenges related to global supply of cell therapies at the “Readiness Strategies for Cell Therapy Commercial Manufacturing” workshop on Thursday, October 4, 2018 at 7:45am PT/10:45am ET.
A live video webcast of the presentations will be available at http://www.meetingonthemesa.com/webcast/.
About Sigilon Therapeutics
Sigilon Therapeutics is creating a new class of living therapeutics to transform the lives of patients with a wide range of chronic diseases, including hemophilia, Type 1 diabetes and lysosomal storage disorders. Our proprietary platform is designed to restore healthy cell and organ function through the implantation of immune-shielded and specially engineered cells in a matrix optimized for cell survival and durability. Sigilon was founded and created by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
